Drug Profile

APR OD031

Alternative Names: Amino acid extended release - APR Applied Pharma Research; APR-OD031

Latest Information Update: 23 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Phenylketonuria
New Molecular Entity No
Available For Licensing Yes

11 Feb 2025 Preclinical development of APR OD031 in Phenylketonuria is still ongoing in Switzerland (PO) (APR Applied Pharma Research pipeline, February 2025)
13 Apr 2020 APR OD031 is available for licensing as of 13 Apr 2020. https://www.apr.ch/applied-pharma-research/healthcare-partners/
26 Mar 2020 Preclinical trials in Phenylketonuria in Switzerland (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com